Green Cross Health (GXH) H2 2026 earnings summary

Executive summary

• Group revenue increased 4% year-over-year to $546.0m, driven by improved medical funding, immunisation incentives, and higher pharmacy dispensary revenue.

• Operating profit (EBIT) rose 17% to $45.3m, reflecting revenue growth and cost control initiatives.

• Net profit after tax attributable to shareholders grew 28% to $20.4m, with EPS at 14.2 cps.

• Final FY26 dividend of 5.50cps declared, payable on 22 June 2026, with a special dividend paid following the divestment of the Community Health division.

• Digital enhancements included new apps and online booking systems for both Pharmacy and Medical divisions.

Financial highlights

• Pharmacy operating revenue up 2% to $380.2m; operating profit up 4% to $22.2m.

• Medical operating revenue up 8% to $165.8m; operating profit up 33% to $26.0m.

• Over 38 million prescription items dispensed and 330,000 vaccinations administered, a 1% increase year-over-year.

• Operating cash flow reached $54.6m; net cash position of $8.6m as of 31 March 2026.

• Gearing ratio reduced to 9.4%; undrawn committed debt facilities of $46.0m.

Outlook and guidance

• Launch of new Primary Health Organisation (Community Care Limited) set for 1 July 2026, strengthening direct funding and frontline services.

• Expansion of Care & Advice Health Hubs and extension of pharmacist scope of practice expected to drive future growth.

• Continued investment in technology, clinical services, targeted refurbishments, and operational efficiency to support revenue and margin growth.

• Pharmacy to advocate for improved funding and expand Care & Advice Health Hubs.